BioSpace News Archive

RaySearch Laboratories AB is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* - including the new ARTemis* OART solution under development - in combination with the Radixact® Treatment Delivery System from Accuray.

Swedish Orphan Biovitrum AB announced its report for the fourth quarter 2023.

We have successfully dosed the first of three patients in Cohort 8, the last cohort of the Phase 1 dose-ranging part of the Phase 1/2 clinical trial in newly diagnosed uMGMT Glioblastoma Multiforme patients.

Closed Loop Medicine Ltd. announced the publication of a peer-reviewed study in the Journal of the American Heart Association .

Zymeworks Inc. announced the appointment of Dr. Alessandra Cesano to its board of directors effective February 8, 2024.

Rockwell Medical, Inc. announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024.

BioCardia, Inc. is targeting heart failure and chronic myocardial ischemia as potential indications for its biotherapeutic candidates: autologous CardiAMP ® cell therapy and allogeneic CardiALLO™ cell therapy.

Prelude Corporation today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.

Soligenix, Inc. announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet’s Disease.

Lucid Diagnostics Inc. today announced that it has contracted with the World Trade Center Health Program (“WTCHP”) to provide the EsoGuard® Esophageal DNA test as a covered benefit to the more than 120,000 responders and survivors who participate in the program.